Log in

Relevant bibliographies by topics / Rotavirus mucosal vaccines

Contents

Journal articles
Book chapters

Academic literature on the topic 'Rotavirus mucosal vaccines'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Rotavirus mucosal vaccines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Rotavirus mucosal vaccines"

1

Chen, Shing C., David H. Jones, Ellen F. Fynan, et al. "Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles." Journal of Virology 72, no. 7 (1998): 5757–61. http://dx.doi.org/10.1128/jvi.72.7.5757-5761.1998.

Full text

Abstract:

DNA vaccines are usually given by intramuscular injection or by gene gun delivery of DNA-coated particles into the epidermis. Induction of mucosal immunity by targeting DNA vaccines to mucosal surfaces may offer advantages, and an oral vaccine could be effective for controlling infections of the gut mucosa. In a murine model, we obtained protective immune responses after oral immunization with a rotavirus VP6 DNA vaccine encapsulated in poly(lactide-coglycolide) (PLG) microparticles. One dose of vaccine given to BALB/c mice elicited both rotavirus-specific serum antibodies and intestinal immun

APA, Harvard, Vancouver, ISO, and other styles

2

Montenegro, Catherine, Federico Perdomo-Celis, and Manuel A. Franco. "Update on Early-Life T Cells: Impact on Oral Rotavirus Vaccines." Viruses 16, no. 6 (2024): 818. http://dx.doi.org/10.3390/v16060818.

Full text

Abstract:

Rotavirus infection continues to be a significant public health problem in developing countries, despite the availability of several vaccines. The efficacy of oral rotavirus vaccines in young children may be affected by significant immunological differences between individuals in early life and adults. Therefore, understanding the dynamics of early-life systemic and mucosal immune responses and the factors that affect them is essential to improve the current rotavirus vaccines and develop the next generation of mucosal vaccines. This review focuses on the advances in T-cell development during

APA, Harvard, Vancouver, ISO, and other styles

3

Lee, Sangun, Boris R. Belitsky, James P. Brinker, et al. "Development of a Bacillus subtilis-Based Rotavirus Vaccine." Clinical and Vaccine Immunology 17, no. 11 (2010): 1647–55. http://dx.doi.org/10.1128/cvi.00135-10.

Full text

Abstract:

ABSTRACT Bacillus subtilis vaccine strains engineered to express either group A bovine or murine rotavirus VP6 were tested in adult mice for their ability to induce immune responses and provide protection against rotavirus challenge. Mice were inoculated intranasally with spores or vegetative cells of the recombinant strains of B. subtilis. To enhance mucosal immunity, whole cholera toxin (CT) or a mutant form (R192G) of Escherichia coli heat-labile toxin (mLT) were included as adjuvants. To evaluate vaccine efficacy, the immunized mice were challenged orally with EDIM EW murine rotavirus and

APA, Harvard, Vancouver, ISO, and other styles

4

Gilfillan, Darby, Allison C. Vilander, Meichen Pan, et al. "Lactobacillus acidophilus Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses." Vaccines 11, no. 12 (2023): 1774. http://dx.doi.org/10.3390/vaccines11121774.

Full text

Abstract:

Rotavirus diarrhea-associated illness remains a major cause of global death in children under five, attributable in part to discrepancies in vaccine performance between high- and low-middle-income countries. Next-generation probiotic vaccines could help bridge this efficacy gap. We developed a novel recombinant Lactobacillus acidophilus (rLA) vaccine expressing rotavirus antigens of the VP8* domain from the rotavirus EDIM VP4 capsid protein along with the adjuvants FimH and FliC. The upp-based counterselective gene-replacement system was used to chromosomally integrate FimH, VP8Pep (10 amino a

APA, Harvard, Vancouver, ISO, and other styles

5

Coste, Alix, Jean-Claude Sirard, Kari Johansen, Jean Cohen, and Jean-Pierre Kraehenbuhl. "Nasal Immunization of Mice with Virus-Like Particles Protects Offspring against Rotavirus Diarrhea." Journal of Virology 74, no. 19 (2000): 8966–71. http://dx.doi.org/10.1128/jvi.74.19.8966-8971.2000.

Full text

Abstract:

ABSTRACT Rotavirus is the major cause of diarrhea among young infants in both humans and animals. Immune protection of newborns by vaccination is difficult to achieve since there is not enough time to mount an immune response before exposure to the virus. We have designed a vaccination strategy mediating transfer of neutralizing antibodies from the mother to the offspring during pregnancy and/or lactation. Adult female mice were nasally immunized with virus-like particles (VLPs) made of viral proteins VP2 and 6 (VLP2/6) or VP 2, 6, and 7 (VLP2/6/7) derived from the RF rotavirus strain in the p

APA, Harvard, Vancouver, ISO, and other styles

6

Hu, Jingping, Jinyuan Wu, Han Cao, et al. "Effects of Rotavirus NSP4 on the Immune Response and Protection of Rotavirus-Norovirus Recombinant Subunit Vaccines in Different Immune Pathways." Vaccines 12, no. 9 (2024): 1025. http://dx.doi.org/10.3390/vaccines12091025.

Full text

Abstract:

Diarrheal disease continues to be a major cause of global morbidity and mortality among children under 5 years of age. To address the current issues associated with oral attenuated rotavirus vaccines, the study of parenteral rotavirus vaccines has promising prospects. In our previous study, we reported that rotavirus nonstructural protein 4 (NSP4) did not increase the IgG antibody titer of co-immune antigen but did have a protective effect against diarrhea via the intramuscular injection method. Here, we explored whether NSP4 can exert adjuvant effects on mucosal immune pathways. In this study

APA, Harvard, Vancouver, ISO, and other styles

7

Otero, Claire E., Stephanie N. Langel, Maria Blasi, and Sallie R. Permar. "Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries." PLOS Pathogens 16, no. 11 (2020): e1009010. http://dx.doi.org/10.1371/journal.ppat.1009010.

Full text

Abstract:

Rotavirus (RV) vaccine efficacy is significantly reduced in lower- and middle-income countries (LMICs) compared to high-income countries. This review summarizes current research into the mechanisms behind this phenomenon, with a particular focus on the evidence that maternal antibody (matAb) interference is a contributing factor to this disparity. All RV vaccines currently in use are orally administered, live-attenuated virus vaccines that replicate in the infant gut, which leaves their efficacy potentially impacted by both placentally transferred immunoglobulin G (IgG) and mucosal IgA Abs con

APA, Harvard, Vancouver, ISO, and other styles

8

Wang, Jun, Songkang Qin, Kuanhao Li, Xin Yin, Dongbo Sun, and Jitao Chang. "Rotavirus Reverse Genetics Systems and Oral Vaccine Delivery Vectors for Mucosal Vaccination." Microorganisms 13, no. 7 (2025): 1579. https://doi.org/10.3390/microorganisms13071579.

Full text

Abstract:

Mucosal immunization represents a promising strategy for preventing enteric infections. Rotavirus (RV), a leading gastrointestinal pathogen distinguished by its remarkable stability and segmented double-stranded RNA genome, has been engineered into a versatile oral vaccine vector through advanced reverse genetics systems. The clinical efficacy of live-attenuated RV vaccines highlights their unique capacity to concurrently induce mucosal IgA responses and systemic neutralizing antibodies, positioning them as a multiple action vector for multiple immune protection. In this review, we summarize t

APA, Harvard, Vancouver, ISO, and other styles

9

Azevedo, Marli S. P., Ana Maria Gonzalez, Lijuan Yuan, et al. "An Oral versus Intranasal Prime/Boost Regimen Using Attenuated Human Rotavirus or VP2 and VP6 Virus-Like Particles with Immunostimulating Complexes Influences Protection and Antibody-Secreting Cell Responses to Rotavirus in a Neonatal Gnotobiotic Pig Model." Clinical and Vaccine Immunology 17, no. 3 (2010): 420–28. http://dx.doi.org/10.1128/cvi.00395-09.

Full text

Abstract:

ABSTRACT We determined the impact of mucosal prime/boost regimens and vaccine type (attenuated Wa human rotavirus [AttHRV] or nonreplicating Wa 2/6 rotavirus-like particles [VLP]) on protection and antibody-secreting cell (ASC) responses to HRV in a neonatal gnotobiotic pig disease model. Comparisons of delivery routes for AttHRV and evaluation of nonreplicating VLP vaccines are important as alternative vaccine approaches to overcome risks associated with live oral vaccines. Groups of neonatal gnotobiotic pigs were vaccinated using combinations of oral (PO) and intranasal (IN) inoculation rout

APA, Harvard, Vancouver, ISO, and other styles

10

MacDonald, Jaime, Michelle J. Groome, Janet Mans, and Nicola Page. "FUT2 Secretor Status Influences Susceptibility to VP4 Strain-Specific Rotavirus Infections in South African Children." Pathogens 9, no. 10 (2020): 795. http://dx.doi.org/10.3390/pathogens9100795.

Full text

Abstract:

Gastroenteritis is a preventable cause of morbidity and mortality worldwide. Rotavirus vaccination has significantly reduced the disease burden, but the sub-optimal vaccine efficacy observed in low-income regions needs improvement. Rotavirus VP4 ‘spike’ proteins interact with FUT2-defined, human histo-blood group antigens on mucosal surfaces, potentially influencing strain circulation and the efficacy of P[8]-based rotavirus vaccines. Secretor status was investigated in 500 children <5 years-old hospitalised with diarrhoea, including 250 previously genotyped rotavirus-positive cases (P[8] =

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Rotavirus mucosal vaccines"

1

Kapikian, Albert Z. "Rotavirus Vaccine: The Clinical Experience with the Rhesus Rotavirus-Based Vaccines." In Mucosal Vaccines. Elsevier, 1996. http://dx.doi.org/10.1016/b978-012410580-5/50027-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Conner, Margaret E., Mary K. Estes, Paul A. Offit, et al. "Development of a Mucosal Rotavirus Vaccine." In Mucosal Vaccines. Elsevier, 1996. http://dx.doi.org/10.1016/b978-012410580-5/50026-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Huys, Adam, Katrina R. Grau, and Stephanie M. Karst. "Development of Oral Rotavirus and Norovirus Vaccines." In Mucosal Vaccines. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-811924-2.00040-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sen, Adrish, Siyuan Ding, and Harry B. Greenberg. "The Role of Innate Immunity in Regulating Rotavirus Replication, Pathogenesis, and Host Range Restriction and the Implications for Live Rotaviral Vaccine Development." In Mucosal Vaccines. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-811924-2.00041-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!